JP2001517206A5 - - Google Patents

Download PDF

Info

Publication number
JP2001517206A5
JP2001517206A5 JP1998509732A JP50973298A JP2001517206A5 JP 2001517206 A5 JP2001517206 A5 JP 2001517206A5 JP 1998509732 A JP1998509732 A JP 1998509732A JP 50973298 A JP50973298 A JP 50973298A JP 2001517206 A5 JP2001517206 A5 JP 2001517206A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1998509732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001517206A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/012868 external-priority patent/WO1998006746A2/en
Publication of JP2001517206A publication Critical patent/JP2001517206A/ja
Publication of JP2001517206A5 publication Critical patent/JP2001517206A5/ja
Withdrawn legal-status Critical Current

Links

JP50973298A 1996-08-16 1997-08-04 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法 Withdrawn JP2001517206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2409896P 1996-08-16 1996-08-16
US60/024,098 1996-08-16
PCT/US1997/012868 WO1998006746A2 (en) 1996-08-16 1997-08-04 Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007284431A Division JP2008044969A (ja) 1996-08-16 2007-10-31 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Publications (2)

Publication Number Publication Date
JP2001517206A JP2001517206A (ja) 2001-10-02
JP2001517206A5 true JP2001517206A5 (https=) 2005-04-07

Family

ID=21818860

Family Applications (5)

Application Number Title Priority Date Filing Date
JP50973298A Withdrawn JP2001517206A (ja) 1996-08-16 1997-08-04 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2007284431A Withdrawn JP2008044969A (ja) 1996-08-16 2007-10-31 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2011168822A Withdrawn JP2012001548A (ja) 1996-08-16 2011-08-01 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2013218131A Withdrawn JP2014012738A (ja) 1996-08-16 2013-10-21 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2016043177A Pending JP2016106137A (ja) 1996-08-16 2016-03-07 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2007284431A Withdrawn JP2008044969A (ja) 1996-08-16 2007-10-31 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2011168822A Withdrawn JP2012001548A (ja) 1996-08-16 2011-08-01 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2013218131A Withdrawn JP2014012738A (ja) 1996-08-16 2013-10-21 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2016043177A Pending JP2016106137A (ja) 1996-08-16 2016-03-07 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Country Status (8)

Country Link
US (1) US6187306B1 (https=)
EP (1) EP0929318B1 (https=)
JP (5) JP2001517206A (https=)
AT (1) ATE283069T1 (https=)
AU (1) AU3889997A (https=)
CA (1) CA2263503C (https=)
DE (1) DE69731756T2 (https=)
WO (1) WO1998006746A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19905501B4 (de) * 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US6541250B2 (en) 2000-06-22 2003-04-01 Aventis Pasteur Limited Continuous adherent melanocyte cell line
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
CN1756568A (zh) * 2002-10-09 2006-04-05 衣阿华中央卫生系统 使用表达α(1,3)-半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫
GB2395270B (en) * 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
SI1889059T1 (sl) 2005-05-27 2009-12-31 Oncimmune Ltd Izboljšani imunotestni postopek
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
CN101632020B (zh) 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
EP2492300B1 (en) * 2009-10-23 2018-10-03 Dow Corning Toray Co., Ltd. Novel organopolysiloxane copolymer
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
KR20240024328A (ko) 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595653A (en) 1981-06-09 1986-06-17 Lee Biomolecular Research Laboratories, Inc. Process for assaying cellular immunity
US5045320A (en) 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
CA2091346C (en) 1990-09-14 2007-04-24 Philip Frost Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU677165B2 (en) * 1991-10-04 1997-04-17 Johns Hopkins University School Of Medicine, The The regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
DK0668350T4 (da) * 1994-02-16 2009-02-23 Us Gov Health & Human Serv Melanomassocieret antigen, epitoper deraf samt vacciner mod melanom
EP0756604A1 (en) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2000502280A5 (https=)
JP2000504603A5 (https=)
JP2000501771A5 (https=)
JP2000501599A5 (https=)
JP2000506880A5 (https=)
JP2001514785A5 (https=)
JP2000512176A5 (https=)
JP2000502472A5 (https=)
JP2000501825A5 (https=)
JP2000515510A5 (https=)
JP2000502425A5 (https=)
JP2000502485A5 (https=)
JP2001508959A5 (https=)
JP2000502568A5 (https=)
JP2000501774A5 (https=)
JP2000502570A5 (https=)
JP2000501876A5 (https=)
JP2000514346A5 (https=)
JP2000501744A5 (https=)
JP2000509217A5 (https=)
JP2001517206A5 (https=)
JP2000502316A5 (https=)
JP2000502714A5 (https=)
JP2000501569A5 (https=)
JP2000508301A5 (https=)